Unicycive Therapeutics (UNCY) Receives Buy Rating with Favorable FDA Outlook, Analysts Predict $6.07 Average Target Price

Unicycive Therapeutics (UNCY) received a Buy rating from H.C. Wainwright, with a price target of $9. The company is advancing its lead drug candidate for chronic kidney disease patients and anticipates a favorable FDA decision, which could significantly impact its market potential. Analysts forecast an average target price of $6.07, implying an upside of 997.51% from the current price of $0.55. The average brokerage recommendation is 1.9, indicating an "Outperform" status.

Unicycive Therapeutics (UNCY), a biotechnology company specializing in kidney disease treatments, has received a Buy rating from H.C. Wainwright with a price target of $9. The company is making significant strides in advancing its lead drug candidate, Oxylanthanum Carbonate (OLC), which is expected to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The anticipated favorable FDA decision could significantly impact the company's market potential.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 28, 2025, for OLC, which is designed to reduce the pill burden for patients from up to twelve chewable tablets to just three pills per day. This improvement in patient compliance could lead to better treatment outcomes for an estimated 500,000 U.S. patients undergoing treatment for hyperphosphatemia.

Analysts forecast an average target price of $6.07, implying an upside of 997.51% from the current price of $0.55. The average brokerage recommendation is 1.9, indicating an "Outperform" status. The company's efforts to have OLC included in updated quality guidelines and its potential to be priced similarly to leading branded drugs in the category position it in a market worth approximately $7 billion.

However, Unicycive's overall financial health score is currently weak, with concerns in profitability and cash flow management. The company concluded the quarter with a cash balance of $19.8 million, expected to fund operations until it reaches its next development milestone. While the company maintains more cash than debt, it experienced a negative free cash flow of $31.1 million in the last twelve months.

Recent developments underscore Unicycive's strategic advancements. The company presented new data at the National Kidney Foundation Spring Clinical Meetings, showcasing its OLC treatment for hyperphosphatemia in chronic kidney disease patients. This data highlighted a reduced pill burden, potentially enhancing patient adherence to the treatment regimen.

Unicycive's New Drug Application for OLC has been accepted, with a critical PDUFA decision date set for June 28, 2025. The company is preparing for a potential commercial launch of OLC in late 2025, aiming to position it competitively in the market.

References:
1. [Investing.com](https://www.investing.com/news/analyst-ratings/benchmark-maintains-3-target-on-unicycive-stock-postq1-filings-93CH-4057041)
2. [Quantisnow](https://quantisnow.com/company/UNCY)